Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Globe Newswire•20/10/2026•07:00 ET
0
Key Highlights
- ➤Visara secures exclusive option for worldwide YOL104 Program rights.
- ➤YOL104-2 targets OSSN, with no FDA-approved therapy currently available.
- ➤Upfront payment required; exercise, milestone, and royalty terms undisclosed.
- ➤YOL104-2 is a trivalent IFN-α peptibody under investigation for OSSN.
- ➤NovaBridge (NBP) owns a majority stake in Visara.
Expert Statements
Jeffrey Nau, President and Chief Executive Officer of Visara
“YOL104-2 represents an attractive potential addition to Visara’s pipeline and aligns well with our strategy to build a differentiated ophthalmology portfolio.”
Jeffrey Nau, President and Chief Executive Officer of Visara
“Through this agreement, we have secured the opportunity to potentially expand our development efforts into an additional area of significant unmet need where there is currently no FDA approved therapy.”
Srishti Gupta, Chief Executive Officer of NovaBridge
“This transaction demonstrates the NovaBridge approach to disciplined portfolio building: identifying differentiated innovation, pairing it with focused operating expertise and advancing opportunities through the structure best suited to each asset.”
Srishti Gupta, Chief Executive Officer of NovaBridge
“By securing an exclusive option to acquire YOL104-2, Visara gains the opportunity to further evaluate a differentiated program in ocular surface disease while maintaining flexibility in capital allocation and portfolio development.”
YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)
Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences
Get started
Create a free account to read the full story.